Spots Global Cancer Trial Database for Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Official Title: Uncontrolled, Open-label, Non-randomized, Phase 1 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Study ID: NCT01096030

Conditions

Neoplasms

Interventions

Regorafenib (Stivarga, BAY73-4506)

Study Description

Brief Summary: This will be an uncontrolled, open-label, non-randomized, phase I study. The primary objectives of this study are to define the pharmacokinetics (PK) and to evaluate the safety and tolerability of Regorafenib administered orally as a single agent in Chinese patients with advanced solid tumors. The secondary objectives are to evaluate tumor response of patients treated with Regorafenib.

Detailed Description: